Fetal Hemoglobin
9
3
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Transfusion-Related Changes in Oxidative Stress Biomarkers in Neonates
Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
Long Term Beta Thalassemia Treatment: Findings From The Extension Period
Fetal Haemoglobin and Cerebral and Peripheral Oxygenation.
The Relevance Between the Level of Fetal Hemoglobin and Short-term Complications in Extremely Preterm Infants
Cord Blood Transfusion In Preterm Neonates (CB-TrIP)
Effect of Broccoli Sprouts Homogenate on SS RBC